Astellas Pharma Inc - Company Snapshot & SWOT Analysis
Astellas Pharma Inc. is a Japanese pharmaceutical company, formed on April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas being a pharmaceutical company focuses on development of innovative drugs and medical solutions. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.
Astellas Pharma reported revenue of USD 12.267 billion for the FY 2018 which saw an increase of 4.75% compared to FY 2017. This revenue is expected to increase by 1% and reach USD 12.39 billion by FY 2019. Astellas Pharma revenue grew at a CAGR of 2.77% during FY 2013 to FY 2018.
Scope of the Astellas Pharma Inc. - Company Snapshot & SWOT Analysis Report
Astellas Pharma reported revenue of USD 12.267 billion for the FY 2018 which saw an increase of 4.75% compared to FY 2017. This revenue is expected to increase by 1% and reach USD 12.39 billion by FY 2019. Astellas Pharma revenue grew at a CAGR of 2.77% during FY 2013 to FY 2018.
Scope of the Astellas Pharma Inc. - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Astellas Pharma Inc. including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Astellas Pharma Inc. - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Astellas Pharma Inc.
3.1.1 Company Profile
3.1.2 Astellas Pharma Inc: in Pharmaceuticals Manufacturing Value Chain
3.1.3 Astellas Pharma Inc: Financial Performance
3.1.3.1 Astellas Pharma Inc: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Astellas Pharma Inc: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Astellas Pharma Inc: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Astellas Pharma Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Astellas Pharma Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7.6 Key Customers of Astellas Pharma Inc.
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
Scope of the Astellas Pharma Inc. - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Astellas Pharma Inc.
3.1.1 Company Profile
3.1.2 Astellas Pharma Inc: in Pharmaceuticals Manufacturing Value Chain
3.1.3 Astellas Pharma Inc: Financial Performance
3.1.3.1 Astellas Pharma Inc: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Astellas Pharma Inc: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Astellas Pharma Inc: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Astellas Pharma Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Astellas Pharma Inc.
Strengths
Weaknesses
Opportunities
Threats
8.7.6 Key Customers of Astellas Pharma Inc.
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
LIST OF EXHIBITS
Exhibit 3.1 Key Information of Astellas Pharma Inc.
Exhibit 3.2 Contact information of Astellas Pharma Inc.
Exhibit 3.3 Astellas Pharma Inc in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Astellas Pharma Inc FY 2013-FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Astellas Pharma Inc FY 2014-FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 3.7 Japan Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.8 Japan Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.9 Americas Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.10 Americas Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.11 EMEA Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.12 EMEA Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.13 Asia & Oceania Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.14 Asia & Oceania Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.15 Therapy Area-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 3.16 Therapy and Geography Area-Wise Revenue of Astellas Pharma Inc FY 2018 (in USD billion)
Exhibit 3.17 SWOT Analysis of Astellas Pharma Inc
Exhibit 3.1 Key Information of Astellas Pharma Inc.
Exhibit 3.2 Contact information of Astellas Pharma Inc.
Exhibit 3.3 Astellas Pharma Inc in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Astellas Pharma Inc FY 2013-FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Astellas Pharma Inc FY 2014-FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 3.7 Japan Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.8 Japan Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.9 Americas Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.10 Americas Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.11 EMEA Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.12 EMEA Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.13 Asia & Oceania Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
Exhibit 3.14 Asia & Oceania Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
Exhibit 3.15 Therapy Area-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
Exhibit 3.16 Therapy and Geography Area-Wise Revenue of Astellas Pharma Inc FY 2018 (in USD billion)
Exhibit 3.17 SWOT Analysis of Astellas Pharma Inc
